Axial involvement in enthesitis-related arthritis: results from a single-center cohort
Authors' conclusion
Axial ERA is a persistent active disease and requires a more aggressive treatment.
Study context
- Population
- Children with enthesitis-related arthritis at the Children's Hospital of Nanjing Medical University, January 2018 to December 2020
- Participants
- 105 children
- Exposure
- Axial enthesitis-related arthritis (ERA) vs peripheral ERA
- Axial ERAn = 57
- Peripheral ERAn = 48reference
- Outcome
- Clinical characteristics and treatment
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Age at disease onset tended to be higher in axial ERA: 11.93 ± 1.72 vs 11.09 ± 1.91 years
- Diagnosis delay bigger in axial ERA: 10.26 ± 11.66 months vs 5.13 ± 7.92 months
- Inflammatory marker levels significantly higher in axial ERA
- Biologics use increased gradually in axial ERA, peaking at 18 months then decreasing; in peripheral ERA peaked at 6 months then declined
Observational data: associations, not effects.
Further findings
Age at disease onset
Diagnosis delay
Hip involvement · more frequent in the axial group
X2 7.033
Treated with bDMARDs at diagnosis
- HLA-B27 positivity · no differences between the groups
- P > 0.05
Age at disease onset
- Age at onset tended to be higher in the axial group
Diagnosis delay
- Diagnosis delay was bigger in axial ERA
Inflammatory marker levels
- Significantly higher in axial ERA
Biologic use over time
- Axial ERA: increased gradually, peaking at 18 months and decreasing thereafter
- Peripheral ERA: peaked at 6 months and began to decline thereafter
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Axial involvement in enthesitis-related arthritis: results from a single-center cohort. Pediatr Rheumatol Online J. Published 6 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →